Business Description
Molecular Partners AG
ISIN : CH0256379097
Total Employee Number:
134Description
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 23.56 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | -0.06 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Book Growth Rate | -31 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 45.67 | |||||
9-Day RSI | 49.56 | |||||
14-Day RSI | 49.37 | |||||
3-1 Month Momentum % | 1.9 | |||||
6-1 Month Momentum % | -1.56 | |||||
12-1 Month Momentum % | 9.78 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 9.42 | |||||
Quick Ratio | 9.42 | |||||
Cash Ratio | 8.95 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.2 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -60.55 | |||||
ROA % | -51.15 | |||||
ROIC % | -974.47 | |||||
3-Year ROIIC % | 1983.27 | |||||
ROC (Joel Greenblatt) % | -1385.05 | |||||
ROCE % | -56.44 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 9 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.71 | |||||
Price-to-Tangible-Book | 1.7 | |||||
EV-to-EBIT | -0.72 | |||||
EV-to-Forward-EBIT | 4.65 | |||||
EV-to-EBITDA | -0.75 | |||||
EV-to-Forward-EBITDA | 4.57 | |||||
EV-to-Forward-Revenue | 2.18 | |||||
EV-to-FCF | -0.86 | |||||
Price-to-GF-Value | 8.4 | |||||
| Price-to-Net-Current-Asset-Value | 1.83 | |||||
| Price-to-Net-Cash | 1.95 | |||||
Earnings Yield (Greenblatt) % | -138.89 | |||||
FCF Yield % | -41.47 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Molecular Partners AG Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.689 | ||
| Beta | 0.389 | ||
| 3-Year Sharpe Ratio | -0.52 | ||
| 3-Year Sortino Ratio | -0.55 | ||
| Volatility % | 35.07 | ||
| 14-Day RSI | 49.37 | ||
| 14-Day ATR (€) | 0.091851 | ||
| 20-Day SMA (€) | 3.342 | ||
| 12-1 Month Momentum % | 9.78 | ||
| 52-Week Range (€) | 2.87 - 4.365 | ||
| Shares Outstanding (Mil) | 37.51 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Molecular Partners AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Molecular Partners AG Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2026 | 2026-08-25 | In 54 days | ||
| Second quarter earnings results for 2026 | 2026-08-25 | In 54 days | ||
| TD Cowen\'s 7th Annual Oncology Innovation Summit | 2026-05-27 11:30 | 3.38 (-1.17%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 3.46 (-1.14%) | ||
| General meeting for 2026 | 2026-04-14 09:00 | 3.48 (-1.69%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-12 16:00 | 4.08 (+1.88%) | ||
| Annual report for 2025 | 2026-03-12 | 4.08 (+1.88%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-12 | 4.08 (+1.88%) | ||
| Guidance call for 2026 | 2026-03-09 16:20 | 4.29 (+1.54%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-02 14:30 | 4.19 (+2.20%) |
Show
Entries
Molecular Partners AG Frequently Asked Questions
What is Molecular Partners AG(STU:6ML)'s stock price today?
The current price of STU:6ML is €3.36. The 52 week high of STU:6ML is €4.37 and 52 week low is €2.87.
When is next earnings date of Molecular Partners AG(STU:6ML)?
The next earnings date of Molecular Partners AG(STU:6ML) is 2026-08-25.
Does Molecular Partners AG(STU:6ML) pay dividends? If so, how much?
Molecular Partners AG(STU:6ML) does not pay dividend.
Press Release
Articles on Molecular Partners AG
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers